TNYA
Tenaya Therapeutics, Inc.
There isn't enough reported data to score TNYA yet.
TNYA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TNYA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
TNYA PE Valuation
TNYA has no meaningful PE right now: it lost money over the past year.
TNYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TNYA's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
TNYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.46 | +$0.31 |
| Q2 2026 | -$0.50 | +$0.45 |
| Q1 2026 | -$0.44 | +$0.71 |
| Q4 2025 | -$0.59 | +$0.72 |
| Q3 2025 | -$0.77 | +$0.68 |
| Q2 2025 | -$0.95 | +$0.59 |
| Q1 2025 | -$1.15 | +$0.50 |
| Q4 2024 | -$1.31 | +$0.37 |
TNYA is still losing money, but far less than before: $0.46 per share over the past year, against $2.76 at its worst in late 2022.
TNYA Quarterly Revenue
TNYA's revenue is growing: $2M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1153% | N/A |
| Q2 2026 | -3972% | N/A |
| Q1 2026 | -8918% | N/A |
TNYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.7M | -$2.1M |
| Q2 2026 | -$3.7M | +$12M |
| Q1 2026 | -$19.2M | +$4.3M |
| Q4 2025 | -$14M | +$4.6M |
| Q3 2025 | -$15.6M | +$4.4M |
| Q2 2025 | -$15.8M | +$7.9M |
| Q1 2025 | -$23.5M | +$5.7M |
| Q4 2024 | -$18.6M | +$3.7M |
TNYA has burned cash in almost every quarter: −$55M over the past year, against −$73M the year before.
TNYA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +8.4M shares |
| 1 year | +39% | +63.2M shares |
| 3 years | +208% | +153M shares |
| 5 years | +731% | +199M shares |
TNYA has 226M diluted shares, up 39% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | $3,000 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $1,000 |
| Q2 2020 | — |
| Q1 2020 | — |
TNYA Net Leverage
TNYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TNYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 7.6 | Oversold |
TNYA's weekly RSI is 30 (oversold) and its Stochastic is 8 (oversold).
TNYA PE vs Healthcare Sector
TNYA has no meaningful PE right now: it lost money over the past year.
TNYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.45 | 22% below |
| 20 week MA | $0.62 | 44% below |
| 50 week MA | $0.71 | 51% below |
| 100 week MA | $0.86 | 59% below |
| 200 week MA | $2.28 | 85% below |
TNYA is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
TNYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $15.4 | $21.4 | +39% |
| 2022 | $21.4 | $1.84 | -91% |
| 2023 | $1.84 | $3.24 | +76% |
| 2024 | $3.24 | $1.50 | -54% |
| 2025 | $1.50 | $0.75 | -50% |
| 2026 YTD | $0.75 | $0.35 | -53% |
TNYA has finished lower in three of the last five years. It's down 53% so far in 2026.